CompanyFerring Pharmaceuticals A/S
ATC codeL01XL10
EU authorised2026-05-28
· 0 yr ago
Flags
Conditional approval
EMA EPAR
Evidence dossier ↗
Adstiladrin CONFIRMED
nadofaragene firadenovec · Non-Muscle Invasive Bladder Neoplasms
Current stage: 4 · first detected 2026-06-25
Also known as: adstiladrin
Status timeline
| Date | Body | Status | Stage | Source |
|---|---|---|---|---|
| 2026-06-25 | EMA | authorised | 4 | link |
| 2026-06-30 | EMA | authorised | 4 | link |
| 2026-07-07 | EMA | authorised | 4 | link |
| 2026-07-14 | EMA | authorised | 4 | link |
| 2026-07-21 | EMA | authorised | 4 | link |
| 2026-07-28 | EMA | authorised | 4 | link |
| 2026-08-04 | EMA | authorised | 4 | link |
| 2026-08-05 | EMA | authorised | 4 | link |
| 2026-08-05 | EMA | authorised | 4 | link |
| 2026-08-11 | EMA | authorised | 4 | link |
| 2026-08-18 | EMA | authorised | 4 | link |